Lek Launching Protein Modification Facility
Mengeš, 23 February - Pharmaceutical company Lek, a subsidiary of Novartis's generics arm Sandoz, will open on Tuesday afternoon a new facility for the production of modified proteins, the Ljubljana-based company announced.
Menges
Lek, a subsidiary of Novartis's generics arm Sandoz, opens a new facility for the production of modified proteins.
Photo: Tamino Petelinsek/STA
Menges
Lek, a subsidiary of Novartis's generics arm Sandoz, opens a new facility for the production of modified proteins.
Photo: Tamino Petelinsek/STA
Menges
Ameet Mallik, the head of biopharmaceuticals department at Sandoz, addressing the opening of a new facility for the production of modified proteins by pharmaceutical company Lek, a subsidiary of Novartis's generics arm Sandoz.
Photo: Tamino Petelinsek/STA
Menges
Health Minister Borut Miklavcic addressing the opening of a new facility for the production of modified proteins by pharmaceutical company Lek, a subsidiary of Novartis's generics arm Sandoz.
Photo: Tamino Petelinsek/STA
The rest of this news item is available to subscribers.
The news item consists of 498 characters (without spaces) or 91 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.